Rail Vision (Nasdaq: RVSN), a development stage technology company seeking to revolutionize railway safety and the data-related market, reported financial results for the third quarter ended September 30, 2023. “We reached another significant milestone in the third quarter with the successful completion of a pilot program with a leading US-based rail and leasing services company. This customer purchased one of our Switch Yard Systems this year and has been impressed with the results on extensive testing. We are now discussing plans with this customer to implement our technology on additional locomotives beginning as soon as Q4 2023. This is a testament to the reliability and effectiveness of our solutions in improving safety and efficiency in rail operations,” commented Shahar Hania, CEO of Rail Vision.

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, announced that Thornton convenience store chain will be featuring Copa di Vino single serve premium wines and Pulpoloco Sangria in Illinois and surrounding areas. The launch will feature (4) varietals of Copa di Vino Premium Wine and (2) varietals of Pulpoloco Sangria. Robert Nistico, Splash Beverage Group’s Chairman and CEO, commented, “As we continue to build our foundation of distribution and retail support, this adds to our availability and footprint as we continue our push across the country.”

Reviva Pharmaceuticals (Nasdaq: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced that it has closed its previously announced registered direct offering with several healthcare-focused institutional investors and an investment vehicle managed by a firm affiliated with a member of the Company’s Board of Directors.

Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximately 51 months from date of the Company’s IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors.